N@N

Isotechnika Pharma presents at the Canadian Dermatology Association Conference

^{Published on 2009-07-06 08:31:56, Last Modified on 2009-07-06 08:32:02 - Market Wire}
 

 EDMONTON, AB, July 6 /CNW/ - Isotechnika Pharma Inc. (TSX:ISA), announced today that three posters were presented by Investigators, in the Phase 3 psoriasis trial (ESSENCE), at the Canadian Dermatology Association's 84th Annual Conference in Vancouver, BC, July 1 - 5. The posters were "Voclosporin (ISA247) Pharmacokinetic-Pharmacodynamic (PK-PD) Profile - Results From ESSENCE Study" presented by Dr. Wayne Gulliver (NewLab Clinical Research Inc., St. John's, NL), "Made in Canada: Development of Voclosporin (ISA247) for the Treatment of Psoriasis" presented by Dr. Charles Lynde (Lynderm Research Inc., Markham, ON), and "Efficacy of Voclosporin (ISA247) for Psoriasis Treatment - Results From the ESSENCE study" presented by Dr. Kim Papp (Probity Medical Research Inc., Waterloo, ON). Interested parties can view the abstracts by visiting the "Presentations" folder in the "For Investors" section of the Company's corporate website at[ www.isotechnika.com ]. About Isotechnika Pharma ------------------------ Edmonton-based Isotechnika Pharma Inc. is a biopharmaceutical company focused on the discovery and development of novel immunosuppressive therapeutics that are designed to offer advantages over other currently available treatments. There is a significant unmet medical need in the treatment of both solid organ transplantation and autoimmune disease. It is estimated that the market potential will exceed $4 billion annually in sales for calcineurin inhibitors such as voclosporin by 2010. Isotechnika Pharma Inc. is a publicly traded company on the Toronto Stock Exchange under the symbol "ISA". More information on Isotechnika Pharma can be found at [ www.isotechnika.com ] or [ www.SEDAR.com ]. Forward-Looking Statements -------------------------- This press release may contain forward-looking statements. Forward looking statements, including the Company's belief as to the potential of its products, the Company's expectations regarding the issuance of additional patents and the Company's ability to protect its intellectual property, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the ability to economically manufacture its products, the potential of its products, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize its products, the ability of the Company to defend its patents from infringement by third parties, and the risk that the Company's patents may be subsequently shown to be invalid or infringe the patents of others. Investors should consult the Company's quarterly and annual filings with the Canadian commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. %SEDAR: 00010508E 

For further information: Dr. Robert Foster, President & CEO, Isotechnika Pharma Inc., (780) 487-1600 (247), (780) 484-4105 (fax), [ rfoster@isotechnika.com ]